FrancophonIA/ELRC3.0 huggingface dataset:
English: This was a phase III randomised, controlled, open-label trial investigating bevacizumab 5.0 mg/kg every 2 weeks or 7.5 mg/kg every 3 weeks in combination with fluoropyrimidine-based chemotherapy versus fluoropyrimidine-based chemotherapy alone in patients with mCRC who have progressed on a first-line bevacizumab-containing regimen.
Danish: Studiet var et fase III randomiseret, kontrolleret, åbent studie, som undersøgte bevacizumab 5,0 mg/kg hver 2. uge eller 7,5 mg/kg hver 3. uge i kombination med fluoropyrimidin-baseret kemoterapi versus fluoropyrimidin-baseret kemoterapi alene, til patienter med metastatisk kolorektalkræft, som progredierede på et1.linje bevacizumab-indeholdende regime.
English: In clinical trials, the overall incidence of arterial thromboembolic reactions ranged up to 3.8% in the bevacizumab-containing arms compared with up to 2.1% in the chemotherapy control arms.
Danish: I kliniske studier var den samlede forekomst af arterielle tromboemboliske bivirkninger op til 3,8 % i bevacizumab-armen sammenlignet med op til 2,1 % i kontrolgruppen, som fik kemoterapi alene.
English: Each vial contains 100 mg bevacizumab in 4 mL of solution or 400 mg bevacizumab in 16 mL of solution.
Danish: Hvert hætteglas indeholder 100 mg bevacizumab i 4 ml opløsning eller 400 mg bevacizumab i 16 ml opløsning.
English: • ML18147: bevacizumab 5.0 mg/kg of body weight every 2 weeks or bevacizumab 7.5 mg/kg of body weight every 3 weeks in combination with fluoropyrimidine/irinotecan or fluoropyrimidine/oxaliplatin in patients with disease progression following first-line treatment with bevacizumab.
Danish: • ML18147: bevacizumab 5,0 mg/kg legemsvægt hver 2. uge eller bevacizumab 7,5 mg/kg legemsvægt hver 3. uge i kombination med fluoropyrimidin/irinotecan eller fluoropyrimidin/oxaliplatin til patienter med sygdomsprogression efter 1.linje-behandling med bevacizumab.
English: 5-Fluorouracil
Danish: Oxaliplatin Leucovorin 5-Fluoruracil
English: Combination of bevacizumab and sunitinib malate
Danish: Kombination af bevacizumab og sunitinibmaleat
English: Detailed information is available on the website of the European Medicines Agency http://www.ema.europa.eu.
Danish: Du kan finde yderligere oplysninger på Det Europæiske Lægemiddelagenturs hjemmeside http://www.ema.europa.eu
English: In clinical trials across all indications the overall incidence of NCI-CTCAE v.3 grade 3-5 bleeding reactions ranged from 0.4% to 6.9% in bevacizumab-treated patients, compared with up to 4.5% of patients in the chemotherapy control group.
Danish: I kliniske studier inden for alle indikationer spændte hyppigheden af NCI-CTCAE v. 3 grad 3-5 blødning fra 0,4 % til 6,9 % hos bevacizumab-behandlede patienter versus 4,5 % hos de patienter, der fik kemoterapi alene.
English: In patients with NSCLC excluding predominant squamous histology, all grade reactions were seen with a frequency of up to 9.3% when treated with bevacizumab plus chemotherapy compared with up to 5% in the patients treated with chemotherapy alone.
Danish: Hos de patienter med NSCLC, der ikke har dominerende planocellulær histologi, der blev behandlet med bevacizumab og kemoterapi, blev der set bivirkninger af alle grader med frekvenser på op til 9,3 % sammenlignet med op til 5 % hos de patienter, der kun blev behandlet med kemoterapi.
English: Eligible patients had persistent, recurrent or metastatic squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix which was not amenable to curative treatment with surgery and/or radiation therapy and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents.
Danish: Studiet inkluderede patienter med persisterende, recidiverende eller metastatisk planocellulært karcinom, adenoskvamøst karcinom eller adenokarcinom i cervix, som ikke kunne kureres med operation og/eller strålebehandling, og som ikke tidligere havde fået behandling med bevacizumab, andre VEGF-hæmmere eller VEGF-receptor-målrettede lægemidler.
English: E4599 was an open-label, randomised, active-controlled, multicentre clinical trial evaluating bevacizumab as first-line treatment of patients with locally advanced (stage IIIB with malignant pleural effusion), metastatic or recurrent NSCLC other than predominantly squamous cell histology.
Danish: Studie E4599 var et åbent, randomiseret, aktivt kontrolleret, multicenter klinisk studie til evaluering af bevacizumab som 1.-linjebehandling af patienter med lokal fremskreden (stadie IIIb med malignt pleural effusion), metastatisk eller recidiverende NSCLC, der ikke har dominerende planocellulær histologi.
English: 16 mL solution in a vial (Type I glass) with a stopper (butyl rubber) containing 400 mg of bevacizumab.
Danish: 16 ml opløsning i et hætteglas (type I glas) med butylgummiprop indeholdende 400 mg bevacizumab.
English: 4 mL solution in a vial (Type I glass) with a stopper (butyl rubber) containing 100 mg of bevacizumab.
Danish: 4 ml opløsning i et hætteglas (type I glas) med butylgummiprop indeholdende 100 mg bevacizumab.
English: Recurrent ovarian cancer
Danish: Recidiverende ovariecancer
English: • PLD 40 mg/m2 as a 1 mg/min IV infusion on day 1 only every 4 weeks.
Danish: • Pegyleret liposomal doxorubicin 40 mg/m2 som 1 mg/min i.v.-infusion, kun på dag 1 hver 4. uge.
English: Overall survival - Primary analysis1 Hazard ratio (95% CI)
Danish: Anden faktor Samlet overlevelse - Primær analyse1 Hazard ratio (95 % konfidensinterval)
English: • a hole in your gut wall,
Danish: • hul i tarmvæggen,
English: Anti-tumour activity was not observed in two earlier studies among a total of 30 children aged > 3 years old with relapsed or progressive high-grade glioma when treated with bevacizumab and irinotecan (CPT 11).
Danish: I to tidligere studier med i alt 30 børn over 3 år med recidiverende eller progredierende høj-grads-gliom blev der ikke observeret antitumor-aktivitet ved behandling med bevacizumab og irinotecan (CPT-11).
English: Efficacy results from study AVF4095g
Danish: Effektresultater fra studie AVF4095g Progressionsfri overlevelse
English: Anorexia Hypomagnesae mia
Danish: Anoreksi Hypomagnesiæmi Hyponatriæmi
English: Results are presented in table 22.
Danish: Resultater vises i tabel 22.
English: MVASI in combination with paclitaxel, topotecan, or pegylated liposomal doxorubicin is indicated for the treatment of adult patients with platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who received no more than two prior chemotherapy regimens and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents (see section 5.1).
Danish: MVASI er, i kombination med paclitaxel, topotecan eller pegyleret liposomal doxorubicin, indiceret til behandling af voksne patienter med platin-resistent recidiverende epitelial ovariecancer, tubacancer eller primær peritonealcancer, som ikke har gennemgået mere end to kemoterapiregimer, og som ikke tidligere har fået behandling med bevacizumab, andre VEGF-hæmmere eller med VEGF-receptor-målrettede lægemidler (se pkt.
English: One hundred and five patients were randomised to 5-FU/FA + placebo arm and 104 patients to 5-FU/FA + bevacizumab (5 mg/kg every 2 weeks) arm. All treatments were continued until disease progression.
Danish: Der blev randomiseret 105 patienter til 5-FU/FA + placebo-armen og 104 patienter til 5FU/FA + bevacizumab-armen (5 mg/kg hver 2. uge).
English: Only patients with histologically documented ovarian, primary peritoneal, or fallopian tube carcinoma that had recurred > 6 months after platinum-based chemotherapy and who had not received chemotherapy in the recurrent setting and who have not received prior therapy with bevacizumab or other VEGF inhibitors or VEGF receptor-targeted agents were included in the study.
Danish: Kun patienter, som havde histologisk dokumenteret ovariecancer, primært peritonealcancer eller tubacancer, som havde recidiv ˃ 6 måneder efter platinbaseret kemoterapi, som ikke havde fået kemoterapi for recidiverende sygdom, og som ikke tidligere havde fået bevacizumab eller behandling med andre VEGF-hæmmere eller VEGF-receptor-målrettede lægemidler, blev inkluderet i studiet.
English: A large phase III trial was designed to investigate the treatment effect of bevacizumab in combination with paclitaxel, as measured by the primary endpoint of PFS. A clinically meaningful and statistically significant improvement in PFS was observed.
Danish: Et stort fase III-studie blev designet for at undersøge behandlingseffekten af bevacizumab i kombination med paclitaxel, målt ved det primære endepunkt progressionsfri overlevelse (PFS).
English: 1,000 mg/m2 oral bid
Danish: 2 timer 1.000 mg/m2 oral to gange daglig
English: Radiotherapy
Danish: Strålebehandling
English: In clinical trials, proteinuria has been reported within the range of 0.7% to 54.7% of patients receiving bevacizumab.
Danish: Proteinuri er blevet rapporteret hos mellem 0,7 % og 54,7 % af patienterne, som fik bevacizumab i kliniske studier.
English: • CPB7.5+ arm: Carboplatin (AUC 6) and paclitaxel (175 mg/m2) for 6 cycles of 3 weeks plus bevacizumab (7.5 mg/kg q3w) for up to 12 months (bevacizumab was started at cycle 2 of chemotherapy if treatment was initiated within 4 weeks of surgery or at cycle 1 if treatment was initiated more than 4 weeks after surgery).
Danish: • CPB7,5+-arm: Carboplatin (AUC 6) og paclitaxel (175 mg/m bevacizumab (7,5 mg/kg hver 3. uge) i op til 12 måneder (bevacizumab blev startet i anden kemoterapiserie, hvis behandling blev initieret inden for 4 uger efter operation, og i første serie, hvis behandling blev initieret mere end 4 uger efter operation).
English: Intestinal obstruction, Recto-vaginal fistulaec,d, Gastrointestinal disorder, Stomatitis, Proctalgia
Danish: Intestinal obstruktion Rektovaginale fistlerc,d Gastrointestinale forstyrrelser Stomatitis
English: Primary endpoint Overall survival (OS)
Danish: Samlet overlevelse (OS)
English: • NO16966: bevacizumab 7.5 mg/kg of body weight every 3 weeks in combination with oral capecitabine and intravenous oxaliplatin (XELOX) or bevacizumab 5 mg/kg every 2 weeks in combination with leucovorin plus 5-fluorouracil bolus, followed by 5-fluorouracil infusion, with intravenous oxaliplatin (FOLFOX-4).
Danish: • NO16966: bevacizumab 7,5 mg/kg legemsvægt hver 3. uge i kombination med oral capecitabin og intravenøs oxaliplatin (XELOX) eller bevacizumab 5 mg/kg hver 2. uge i kombination med leucovorin plus 5-fluoruracil bolus efterfulgt af 5-fluoruracil infusion og intravenøs oxaliplatin (FOLFOX-4).
English: In clinical trials of ovarian cancer, grade 3-5 wound healing complications were observed in up to 1.8% of patients in the bevacizumab arm versus 0.1% in the control arm (NCI-CTCAE v.3).
Danish: I kliniske studier af ovariecancer blev der observeret sårhelingskomplikationer af grad 3-5 hos op til 1,8 % af patienterne i bevacizumab-armen i forhold til 0,1 % i kontrolarmen (NCI-CTCAE v. 3).
English: Hazard ratio (95% CI) (registration form)b
Danish: Hazard ratio (95 % konfidensinterval) (registrerings-form)b p-værdi
English: Pulmonary hypertensionc, Nasal septum perforationc
Danish: Pulmonal hypertensionc Næseseptum perforationc
English: Information on foetal malformations observed in the post-marketing setting are provided in sections 4.6 and 4.8.
Danish: Information om føtale misdannelser observeret efter markedsføring er angivet i pkt.
English: Febrile neutropenia, Leucopenia, Neutropeniab Thrombocytope nia
Danish: Febril neutropeni Leukopeni Neutropenib Trombocytopeni
English: MVASI will be administered together with a chemotherapy regimen containing platinum.
Danish: MVASI vil blive givet sammen med kemoterapibehandling, der indeholder platin.
English: There have been rare reports of bevacizumab-treated patients developing signs and symptoms that are consistent with PRES, a rare neurological disorder.
Danish: Der har været sjældne rapporter om symptomer, der stemmer overens med PRES, en sjælden neurologisk forstyrrelse, hos bevacizumab-behandlede patienter.
English: Ovarian failureb,c,d
Danish: Ovariesvigtb,c,d
English: Cisplatin/Gemcitabine + bevacizumab 15 mg/kg q 3 weeks
Danish: Cisplatin/Gemcitabin + bevacizumab 15 mg/kg hver 3. uge
English: Posterior Reversible Encephalopathy Syndrome (PRES) (see section 4.8)
Danish: Posteriort reversibelt encefalopati-syndrom (PRES) (se pkt.
English: The primary endpoint was progression-free survival, with secondary endpoints including objective response rate and overall survival.
Danish: Det primære endepunkt var progressionsfri overlevelse; de sekundære endepunkter omfattede objektiv responsrate og samlet overlevelse.
English: • CT + BV arm (chemotherapy plus bevacizumab):
Danish: • Kemoterapi + bevacizumab-armen:
English: Topotecan + Paclitaxel vs. Cisplatin + Paclitaxel
Danish: Topotecan + paclitaxel vs cisplatino + paclitaxel
English: There have also been less common reactions of minor mucocutaneous haemorrhage in other locations, such as gingival bleeding or vaginal bleeding.
Danish: Mindre slimhindeblødninger lokaliseret andre steder, som f.eks. gingival eller vaginal blødning, har også været rapporteret som mindre almindelige bivirkninger.
English: The primary analysis of investigator assessed PFS with a data cut-off date of 28 February 2010 shows an unstratified hazard ratio of 0.79 (95% CI: 0.68-0.91, 2-sided log-rank p-value 0.0010) with a median PFS of 16.0 months in the CP arm and 18.3 months in the CPB7.5+ arm.
Danish: Den primære analyse af investigatorvurderet PFS med cut-off den 28. februar 2010 viser en ustratificeret hazard ratio på 0,79 (95 % konfidensinterval: 0,68-0,91, tosidig log-rank p-værdi 0,0010) med en median PFS på 16,0 måneder i CP-armen og 18,3 måneder i CPB7,5+-armen.
English: • Each 4 mL vial contains 100 mg of bevacizumab, corresponding to 1.4 mg/mL when diluted as recommended.
Danish: • Hvert 4 ml hætteglas indeholder 100 mg bevacizumab svarende til 1,4 mg/ml efter foreskreven fortynding.
English: This was a phase II randomised, active-controlled, open-labelled clinical trial investigating bevacizumab in combination with 5-FU/FA as first-line treatment of metastatic colorectal cancer.
Danish: Studiet var et åbent, randomiseret, aktivt kontrolleret, klinisk fase II-studie, som undersøgte bevacizumab i kombination med 5-FU/FA som 1.-linjebehandling af metastatisk kolorektalkræft.
English: In locally recurrent and metastatic breast cancer trials, grade 3-5 wound healing complications were observed in up to 1.1% of patients receiving bevacizumab compared with up to 0.9% of patients in the control arms (NCI-CTCAE v.3).
Danish: I kliniske studier omhandlende lokalt recidiverende eller metastatisk brystkræft blev der observeret sårhelingskomplikationer af grad 3-5 hos op til 1,1 % af patienterne, som fik bevacizumab, og hos op til 0,9 % af patienterne i kontrolarmene (NCI-CTCAE v. 3).
English: Exploratory analysis; OS updated analysis at clinical cut-off on 28 October 2015, approx. 45% patient had died and OS is therefore considered immature.
Danish: * Eksploratorisk analyse, opdateret analyse af samlet overlevelse på klinisk cut-off 28. oktober 2015, hvor ca.
English: Gallbladder perforationa,b
Danish: Gastrointestinal perforationa,b
English: (16.2 vs. 12.0 months; p = 0.1342)
Danish: (16,2 vs 12,0 måneder: p =
English: (12.0 vs. 15.0 months;
Danish: (12,0 vs 15,0 måneder; p =
English: Seventy-one patients were randomised to receive bolus 5-FU/FA or 5-FU/FA + bevacizumab (5 mg/kg every 2 weeks).
Danish: Der blev randomiseret 71 patienter til bolus 5-FU/FA eller 5-FU/FA + bevacizumab (5 mg/kg hver 2. uge).
English: The percentage of patients with an ECOG PS of 1 or ≥ 2 was 38.7% and 5.0% in the CT arm, and 29.8% and 9.0% in the CT + BV arm. Information on race exists for 29.3% of patients and nearly all patients were white.
Danish: Procentdelen af patienter med ECOG-performancestatus 1 eller ≥ 2 var henholdsvis 38,7 % og 5,0 % i kemoterapi-armen og 29,8 % og 9,0 % i kemoterapi + bevacizumabarmen.
English: The median age was 46.0 years (range: 20-83) in the chemo alone group and 48.0 years (range: 22-85) in the chemo + bevacizumab group; with 9.3% of patients in the chemo alone group and 7.5% of patients in the chemo + bevacizumab group over the age of 65 years.
Danish: Medianalder var 46,0 år (spændvidde: 20-83) i kemoterapigruppen og 48,0 år (spændvidde: 22-85) i kemoterapi + bevacizumab-gruppen.
English: The efficacy results are presented in table 12.
Danish: Effektresultaterne er præsenteret i tabel 12.
English: Addition of bevacizumab to standard of care did not demonstrate clinical benefit in clinical trial BO20924, in 71 evaluable children (from age 6 months to less than 18 years old) patients with metastatic rhabdomyosarcoma and non-rhabdomyosarcoma soft tissue sarcoma (see section 4.2 for information on paediatric use).
Danish: I et klinisk studie BO20924 gav tilføjelse af bevacizumab til standardbehandlingen ingen kliniske fordele hos 71 evaluérbare børn (fra 6 måneder til under 18 år) med metastatisk rabdomyosarkom og ikkerabdomyosarkom bløddelssarkom.
English: Patients may be at risk of developing venous thromboembolic reactions, including pulmonary embolism under bevacizumab treatment.
Danish: Patienter i behandling med bevacizumab kan have risiko for at udvikle venøse tromboemboliske bivirkninger, herunder lungeemboli.
English: Each vial of 16 mL of concentrate contains 400 mg of bevacizumab.
Danish: Hvert hætteglas med 16 ml koncentrat indeholder 400 mg bevacizumab.
English: When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back at least 6 months after the last time they were treated with a chemotherapy regimen containing a platinum agent, MVASI will be administered in combination with carboplatin and gemcitabine or with carboplatin and paclitaxel.
Danish: Når lægemidlet anvendes til voksne patienter med fremskreden kræft i æggestokkene, kræft i æggelederne eller primær bughindekræft, hvor sygdommen er kommet igen mere end 6 måneder efter sidste kemoterapi, som indeholdt platin, vil MVASI blive givet sammen med carboplatin og gemcitabin eller sammen med carboplatin og paclitaxel.
English: • Carboplatin (AUC 4, day 1) and gemcitabine (1,000 mg/m2 on days 1 and 8) and concurrent bevacizumab (15 mg/kg day 1) every 3 weeks for 6 and up to 10 cycles followed by bevacizumab (15 mg/kg every 3 weeks) alone until disease progression or unacceptable toxicity.
Danish: • Carboplatin (AUC 4, dag 1) og gemcitabin (1.000 mg/m2 på dag 1 og 8) samtidig med bevacizumab (15 mg/kg, dag 1) hver 3. uge i 6 og op til 10 behandlingsserier, efterfulgt af bevacizumab (15 mg/kg hver 3. uge) som monoterapi indtil sygdomsprogresssion eller uacceptabel toksicitet.
English: • Each 16 mL vial contains 400 mg of bevacizumab, corresponding to 16.5 mg/mL when diluted as recommended.
Danish: • Hvert 16 ml hætteglas indeholder 400 mg bevacizumab svarende til 16,5 mg/ml efter foreskreven fortynding.
English: (p-value5 < 0.0001)
Danish: (p-værdi5 < 0,0001)
English: The secondary endpoint of overall survival was not mature.
Danish: Data for det sekundære endepunkt, den samlede overlevelse, er ikke tilgængelige endnu.
English: The addition of bevacizumab 5 mg/kg every two weeks to 5-FU/FA resulted in higher objective response rates, longer progression-free survival, and a trend in longer survival, compared with 5-FU/FA chemotherapy alone (see table 5).
Danish: Sammenlignet med 5-FU/FA-kemoterapi alene medførte tillæg af bevacizumab 5 mg/kg hver 2. uge til 5-FU/FA en højere, objektiv responsrate, længere progressionsfri overlevelse og en tendens til længere overlevelse (se tabel 5).
English: When used for those adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose disease has come back before 6 months after the last time they were treated with a chemotherapy regimen containing a platinum agent, MVASI will be administered in combination with paclitaxel, or topotecan, or pegylated liposomal doxorubicin.
Danish: Når lægemidlet anvendes til voksne patienter med fremskreden kræft i æggestokkene, kræft i æggeledere eller primær bughindekræft, hvor sygdommen er kommet igen tidligere end 6 måneder efter sidste kemoterapi, som indeholdt platin, vil MVASI blive givet sammen med paclitaxel eller topotecan eller pegyleret liposomal doxorubicin.
English: In the FOLFOX treatment subgroup, the median PFS was 8.6 months in placebo and 9.4 months in bevacizumab-treated patients, HR = 0.89, 97.5% CI = [0.73; 1.08]; p-value = 0.1871, the corresponding results in the XELOX treatment subgroup being 7.4 vs. 9.3 months, HR = 0.77, 97.5% CI = [0.63; 0.94]; p-value = 0.0026.
Danish: I FOLFOX undergruppen var den mediane PFS 8,6 måneder i placebogruppen vs 9,4 måneder for bevacizumab-behandlede patienter, HR = 0,89, 97,5 % konfidensinterval = [0,73-1,08]; p-værdi = 0,1871.
English: Secondary endpoint Progression-free survival (PFS)
Danish: Sekundært endepunkt Progressionsfri overlevelse
English: Each vial of 4 mL of concentrate contains 100 mg of bevacizumab.
Danish: Hvert hætteglas med 4 ml koncentrat indeholder 100 mg bevacizumab.
English: Congestive heart failureb,d, Supraventricular tachycardia
Danish: Kongestivt hjertesvigtb,d Supraventrikulær takykardi
English: 85 mg/m2 IV 2 h
Danish: 85 mg/m i.v.
English: Examples include palmar-plantar erythrodysaesthesia syndrome with pegylated liposomal doxorubicin or capecitabine, peripheral sensory neuropathy with paclitaxel or oxaliplatin, nail disorders or alopecia with paclitaxel and paronychia with erlotinib.
Danish: Nogle af bivirkningerne er almindelige ved behandling med kemoterapi, men bevacizumab kan forværre disse bivirkninger, når det gives i kombination med kemoterapi, f.eks. palmoplantar erytrodysæstesisyndrom med pegyleret liposomal doxorubicin eller capecitabin, perifer sensorisk neuropati med paclitaxel eller oxaliplatin, negleproblemer og alopeci med paclitaxel og paronykie med erlotinib.
English: Patients with untreated CNS metastases were routinely excluded from clinical trials with bevacizumab, based on imaging procedures or signs and symptoms.
Danish: Patienter med ubehandlede CNS-metastaser, verificeret ved billeddiagnostik eller tegn og symptomer, er rutinemæssigt blevet udeladt af kliniske studier med bevacizumab.
English: Dyspnoea, Rhinitis, Epistaxis, Cough
Danish: Fistlerb,d Muskelsvaghed Rygsmerter
English: No adverse events leading to death occurred in either treatment arm; all deaths were attributed to disease progression.
Danish: I begge behandlingsarme var der ingen bivirkninger som resulterede i dødsfald.
English: p-value3,4 Objective response rate5
Danish: Objektiv responsrate5
English: The efficacy results are presented in table 14.
Danish: Effektresultater er præsenteret i tabel 14.
English: The median overall survival was 20.3 months in placebo and 21.2 months in bevacizumab-treated patients in the FOLFOX treatment subgroup, HR = 0.94, 97.5% CI = [0.75; 1.16]; p-value = 0.4937, the corresponding results in the XELOX, treatment subgroup being 19.2 vs. 21.4 months, HR = 0.84, 97.5% CI = [0.68; 1.04]; p-value = 0.0698.
Danish: Den mediane, samlede overlevelse var 20,3 måneder for placebogruppen vs 21,2 måneder for bevacizumab-behandlede patienter i FOLFOX undergruppen, HR = 0,94, 97,5 % konfidensinterval = [0,75-1,16]; p-værdi = 0,4937.
English: CT (n = 182)
Danish: Kemoterapi (n = 182)
English: • CPB arm: Carboplatin (AUC5) and paclitaxel (175 mg/m2 IV) and concurrent bevacizumab
Danish: • CPB arm: Carboplatin (AUC 5) og paclitaxel (175 mg/m i.v.)
English: The majority of the patients in each treatment arm (74% and 71%) had poorly differentiated (grade 3)
Danish: Størstedelen af patienterne i de 2 behandlingsarme (74 % og 71 %) havde lavt differentierede (grad 3) (NCI-CTCAE v. 3) primære tumorer ved baseline.
English: Patients with measurable disease at baseline.
Danish: Patienter med målbar sygdom ved baseline.
English: MVASI is a medicine used for the treatment of adult patients with advanced cancer in the large bowel, i.e., in the colon or rectum.
Danish: MVASI er medicin, som anvendes hos voksne til behandling af fremskreden kræft i tyktarmen eller endetarmen.